Merck KGaA Says EU Backs Wider Use of MS Drug Rebif

Merck KGaA (MRK) said the European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the wider use of Rebif for relapsing forms of multiple sclerosis.

To contact the editor responsible for this story: Ragnhild Kjetland at rkjetland@bloomberg.net

Bloomberg reserves the right to edit or remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.